We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ESPR market cap is 372.4M. The company's latest EPS is USD -1.0620 and P/E is -1.77.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 33.97M | 32.25M | 137.74M | 73.83M | 51.63M |
| Operating Income | -27.53M | -42.37M | 72.27M | 2.58M | -16.03M |
| Net Income | -41.25M | -56.34M | 61.02M | -61.93M | -29.52M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 148.36M | 227.55M | 78.45M | 75.48M | 116.33M |
| Operating Income | -93.1M | -121.4M | -226.73M | -179.5M | -155.56M |
| Net Income | -97.17M | -143.55M | -269.11M | -233.66M | -209.25M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 221.31M | 205.8M | 373.06M | 352.32M | 314.11M |
| Total Liabilities | 631.31M | 660.79M | 667.36M | 696.54M | 684.32M |
| Total Equity | -410M | -454.99M | -294.3M | -344.22M | -370.21M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 214.45M | 353.26M | 381.59M | 247.94M | 205.8M |
| Total Liabilities | 194.5M | 449.39M | 578.53M | 571.72M | 660.79M |
| Total Equity | 19.95M | -96.13M | -196.94M | -323.78M | -454.99M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -98.43M | -135.49M | 53.83M | 46.62M | 11.3M |
| Investing | 42.5M | 42.5M | -73k | -150k | -317k |
| Financing | 45.99M | 50.46M | 90.61M | 60.58M | 51.49M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -70.34M | -85.18M | -263.81M | -174.83M | -135.49M |
| Investing | 64.23M | 21.36M | -50.48M | 8.1M | 42.5M |
| Financing | 136.2M | 201.73M | 268.22M | 32.61M | 50.46M |
| Market Cap | 372.4M |
| Price to Earnings Ratio | -1.77 |
| Price to Sales Ratio | 3.18 |
| Price to Cash Ratio | 4.5 |
| Price to Book Ratio | -0.81 |
| Dividend Yield | - |
| Shares Outstanding | 197.04M |
| Average Volume (1 week) | 4.23M |
| Average Volume (1 Month) | 4.88M |
| 52 Week Change | -13.70% |
| 52 Week High | 3.94 |
| 52 Week Low | 1.58 |
| Spread (Intraday) | 0.01 (0.53%) |
| Company Name | Esperion Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.esperion.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
